Keros Total Stockholder Equity from 2010 to 2025
| KROS Stock | USD 10.99 0.02 0.18% |
Total Stockholder Equity | First Reported 2019-03-31 | Previous Quarter 532.8 M | Current Value 571.6 M | Quarterly Volatility 148.4 M |
Check Keros Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Keros Therapeutics' main balance sheet or income statement drivers, such as Tax Provision of 285 K, Net Interest Income of 0.0 or Interest Income of 3.1 M, as well as many indicators such as Price To Sales Ratio of 159, Dividend Yield of 0.0 or PTB Ratio of 0.99. Keros financial statements analysis is a perfect complement when working with Keros Therapeutics Valuation or Volatility modules.
Keros | Total Stockholder Equity |
Latest Keros Therapeutics' Total Stockholder Equity Growth Pattern
Below is the plot of the Total Stockholder Equity of Keros Therapeutics over the last few years. It is the total equity held by shareholders, calculated as the difference between a company's total assets and total liabilities. It represents the net value of the company owned by shareholders. Keros Therapeutics' Total Stockholder Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Keros Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Stockholder Equity | 10 Years Trend |
|
Total Stockholder Equity |
| Timeline |
Keros Total Stockholder Equity Regression Statistics
| Arithmetic Mean | 150,405,478 | |
| Geometric Mean | 42,121,957 | |
| Coefficient Of Variation | 137.48 | |
| Mean Deviation | 172,972,723 | |
| Median | 12,758,000 | |
| Standard Deviation | 206,774,562 | |
| Sample Variance | 42755.7T | |
| Range | 594.7M | |
| R-Value | 0.84 | |
| Mean Square Error | 13489.7T | |
| R-Squared | 0.71 | |
| Significance | 0.000047 | |
| Slope | 36,480,472 | |
| Total Sum of Squares | 641335.8T |
Keros Total Stockholder Equity History
About Keros Therapeutics Financial Statements
Keros Therapeutics shareholders use historical fundamental indicators, such as Total Stockholder Equity, to determine how well the company is positioned to perform in the future. Although Keros Therapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Keros Therapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Keros Therapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Stockholder Equity | 571.6 M | 600.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Keros Stock Analysis
When running Keros Therapeutics' price analysis, check to measure Keros Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Keros Therapeutics is operating at the current time. Most of Keros Therapeutics' value examination focuses on studying past and present price action to predict the probability of Keros Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Keros Therapeutics' price. Additionally, you may evaluate how the addition of Keros Therapeutics to your portfolios can decrease your overall portfolio volatility.